Inclusion of patients with reduced performance status (ECOG 2 or higher) in FDA registrational trials for renal cell carcinoma (RCC). - KIVIRID

Inclusion of patients with reduced performance status (ECOG 2 or higher) in FDA registrational trials for renal cell carcinoma (RCC).

Authors: Ronit Juthani, Panah Parab, Kala Seetharaman

Published: 2025-02-18

DOI: 10.1200/jco.2025.43.5_suppl.453

Source: Full article

Abstract

453